Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes — ACCESS MANTA  

Femoral Arteriotomy Closure Clinical Trial

Official title: Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes

Status Recruiting

Clinical Trial Summary

This is an observational study designed to evaluate the safety and clinical outcomes of the MANTA® Vascular Closure Device (VCD) (the MANTA® Device) in TAVR procedures. The study will enroll participants who are undergoing a TAVR procedure. The purpose of this study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access.

Clinical Trial Description

In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures. In Israel, the 14F MANTA® is indicated for closure of femoral arterial access sites following the use of 10-14F devices or sheaths (maximum OD/profile of 18F), and the 18F MANTA® device is indicated for closure of femoral arterial access sites following the use of 15-18F devices or sheaths (maximum OD/profile of 25F). The purpose of the study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access. ;

Related Conditions & MeSH terms

• Femoral Arteriotomy Closure

• NCT number: NCT05936996
• Study type: Observational [Patient Registry]
• Source: Essential Medical, Inc.
• Contact: Farah Jarjous
• Phone: +1.734.309.1312
• Email: farah.jarjous@teleflex.com
• Status: Recruiting
• Start date: November 15, 2023
• Completion date: March 31, 2025